CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Ardelyx Q3 product revenue rises 19%, loss narrows

By Reuters News


Overview

  • Biopharmaceutical company's Q3 product revenue grew 19% yr/yr to $125.5 mln

  • Company reported Q3 net loss of $0.7 mln, slightly narrower than last year

  • Company completed Phase 3 ACCEL trial enrollment for CIC ahead of schedule


Outlook

  • Company reiterates 2026 IBSRELA revenue guidance of $350 mln to $370 mln

  • Company maintains 2026 XPHOZAH revenue guidance of $110 mln to $120 mln

  • Ardelyx expects 2026 operating expenses to remain below $500 mln


Result Drivers

  • IBSRELA DEMAND - Co said 23% yr/yr revenue growth for IBSRELA was driven by increases in total writers and total prescriptions

  • XPHOZAH SALES - XPHOZAH revenue grew 7% yr/yr, contributing to total product revenue growth

  • COMMERCIAL INVESTMENT - SG&A expenses rose due to investments to address access barriers and drive future IBSRELA adoption


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Sales

$125.46 mln

Q3 Net Loss

$737,000

Q3 Operating Income

$4.02 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Ardelyx, Inc. is $13.70, about 352.1% above its November 2 closing price of $3.03

  • The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 20 three months ago


Reuters Recommended Reads

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

  • Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.